Eylea Biosimilar Developer Momenta To Be Acquired By J&J For $6.5bn

M710 Aflibercept Candidate To Be Filed In 2021

 
• By Dean Rudge

Momenta Pharmaceuticals has signed an agreement to be acquired by Johnson & Johnson, with the deal to include, for now, the M710 biosimilar aflibercept candidate being developed with Mylan.

Close-up of blue eye. High Technologies in the futuristic. : cataract
Momenta and Mylan's Eylea biosimilar is set to pass into J&J's hands • Source: Shutterstock

More from Deals

More from Business